

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
05 August 2021 (05.08.2021)



(10) International Publication Number
WO 2021/152165 A1

(51) International Patent Classification:
C07D 498/22 (2006.01) A61P 35/00 (2006.01)
A61K 31/529 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/EP2021/052255

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

(22) International Filing Date:
01 February 2021 (01.02.2021)

(25) Filing Language: English

(26) Publication Language: English

Published:

- with international search report (Art. 21(3))

(30) Priority Data:
20154852.6 31 January 2020 (31.01.2020) EP

(71) Applicant: **ONCODESIGN S.A.** [FR/FR]; 20, Rue Jean
Mazen B.P. 27 627, 21076 Dijon Cedex (FR).

(72) Inventors: **LAMOTTE, Yann**; Centre de Recherches
François Hyafil, 25-27 avenue du Québec, 91140 Ville-
bon sur Yvette (FR). **DODIC, Nérina**; Centre de recherche
François HYAFIL, 25 avenue du Québec, 91951 Les Ulis
cedex (FR). **TAP, Aurélien**; 5 rue Victor Schoelcher, 91160
Saulx les Chartreux (FR). **DENIS, Alexis**; 186 Bd Voltaire,
75011 Paris (FR). **BRUSQ, Jean-Marie**; 24 grande rue,
78720 Dampierre en Yvelines (FR). **DAOUBI KHAM-
LICH, Mourad**; Eurofins Villapharma Research, Car-
retera el Estrecho – Lobosillo Km 2.5, Avda. Azul, 30320
Murcia (ES). **BENDERITTER, Pascal André René**; 18,
rue Marie de Bourgogne, 21950 St Apollinaire (FR).

(74) Agent: **ARNOLD & SIEDSMA BV**; Bezuidenhoutseweg
57, 2594 AC The Hague (NL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: MACROCYCLIC RIP2-KINASE INHIBITORS

(57) Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2-kinase, and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.

